Bridgeway Capital Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Bridgeway Capital Management’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-120,300	Closed	-$84K	–	1482
2023 Q1	$84K	Buy	120,300 +50,000	+71%	+$46K	﹤0.01%	1263
2022 Q4	$63.3K	Sell	70,300 -45,000	-39%	-$130K	﹤0.01%	1276
2022 Q3	$692K	Sell	115,300 -12,000	-9%	-$68.1K	0.02%	816
2022 Q2	$527K	Buy	127,300 +10,000	+9%	+$35.3K	0.01%	865
2022 Q1	$446K	Buy	117,300 +12,000	+11%	+$54.1K	0.01%	969
2021 Q4	$474K	Sell	105,300 -30,000	-22%	-$152K	0.01%	993
2021 Q3	$630K	Buy	135,300 +110,300	+441%	+$584K	0.01%	969
2021 Q2	$176K	Hold	25,000	–	–	﹤0.01%	1275
2021 Q1	$148K	Hold	25,000	–	–	﹤0.01%	1304
2020 Q4	$115K	Buy	+25,000	New	+$108K	﹤0.01%	1259

Bridgeway Capital Management's STSA Position: Q2 2023 in Review

Bridgeway Capital Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 120,300 shares — an estimated $84K sold.

Bridgeway Capital Management first reported a position in STSA in Q4 2020 and held it in 10 quarters. The position peaked at $692K in Q3 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Bridgeway Capital Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bridgeway Capital Management sold 120,300 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $84K.
Bridgeway Capital Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Bridgeway Capital Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $692K in Q3 2022.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Bridgeway Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.